Neurogene Inc.

NEW YORK, NY · Founded 2018 · CIK 0001768250 · Biotech · Public

Gene therapies for rare neurological diseases

neurogene.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$106M
2 Form D · Dec 2020
69 months since last filing
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$37,500,001
Private capital raisedForm D · SEC$68,999,980
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2819STEL Technologies, LLC——
2820Passage Bio—$110M
2821Acadia Pharmaceuticals—$107M
2822Neurogene Inc.—$106M
2823Ovid Therapeutics—$106M
2824LEAP THERAPEUTICS, INC.—$105M
2825CENTRILLION BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Robert BaffiDirector
  • Stephen BiggarDirector
  • Christine CvijicExecutive Officer
  • Cory FreedlandDirector
  • Rachel McMinnDirector · Executive Officer
  • Srdjan StankovicDirector
  • Caroline StoutDirector

Patents

USPTO · 0 granted of 5
  • NEO-2/15 Variants and Uses Thereof for Preferentially Stimulating T-Regulatory Cellsapplication
  • Polypeptides And Uses Thereof For Preferentially Stimulating T-regulatory Cellsapplication
  • Recombinant Optimized Galc Constructs And Methods For Treating Galc-associated Disordersapplication
  • INTERLEUKIN-2 Receptor Beta (IL-2RB) Binding Polypeptidesapplication
  • Recombinant Optimized GALC Constructs and Methods for Treating GALC-Associated Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.